Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute gut graft-versus-host disease after pediatric allogeneic stem cell transplantation

摘要

Primary Immunodeficiency Syndromes are fast gaining momentum in the velocity of the diagnosis due to the easier accessibility of the tests and high index of suspicion. The accuracy of the diagnosis and a curative treatment available i.e. bone marrow transplant has led to an interest in devising better conditioning protocols and guidelines for management. In a country like India where such children can succumb to life threatening infections, one must not waste time is searching for un- related donor but plan a haploidentical transplant. We report two such rare cases first being Wiskott Aldrich Syndrome and second Chediak Higashi Syndrome who underwent haploidentical HSCT at our centre. The objective is to promote Haploidentical HSCT in PIDs Background and objective: Anti-CD(25) monoclonal antibodies (Mabs) have been evaluated for the treatment of steroid-refractory acute graft-versus-host disease (GVHD) in patients undergoing hematopoietic stem cell transplantation (HSCT) mainly in adults after matched donors for years, but there is paucity of data in pediatric patients. Our objective is to evaluate the efficacy of the chimeric Mab, basiliximab in pediatric patients with steroid-refractory acute gut GVHD after matched sibling and haploidentical HSCT.